Tendency in Pulmonary Aspergillosis Investigation during the Covid-19 Era

What Is Changing

Bibliographic Data

ID15499072
AuthorsGiuseppina Caggiano (0000-0003-3009-9147, University of Bari Aldo Moro, corresponding author), Francesca Apollonio (0000-0002-2601-0894, University of Bari Aldo Moro), Mila Consiglio (University of Bari Aldo Moro), Valentina Gasparre (University of Bari Aldo Moro), Paolo Trerotoli (0000-0001-7102-9108, University of Bari Aldo Moro), Giusy Diella (University of Bari Aldo Moro), Marco Lopuzzo (University of Bari Aldo Moro), Francesco Triggiano (0009-0007-3858-3669, University of Bari Aldo Moro), Stefania Stolfa (0000-0002-8856-4606, University of Bari Aldo Moro), Adriana Mosca (0000-0002-7646-2370, University of Bari Aldo Moro), Maria Teresa Montagna (0000-0002-2958-5458, University of Bari Aldo Moro)
Year2022
Volume19
Issue12
Pages7079-7079
Publication date2022-06-09
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueInternational Journal of Environmental Research and Public Health (JOURNAL)
Journal identifiersISSN: 1661-7827 • E-ISSN: 1660-4601
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/ijerph19127079
PMID35742328
OpenAlexW4281613787
LanguageEN
References cited50

Aspergillosis is a disease caused by Aspergillus , and invasive pulmonary aspergillosis (IPA) is the most common invasive fungal infection leading to death in severely immuno-compromised patients. The literature reports Aspergillus co-infections in patients with COVID-19 (CAPA). Diagnosing CAPA clinically is complex since the symptoms are non-specific, and performing a bronchoscopy is difficult. Generally, the microbiological diagnosis of aspergillosis is based on cultural methods and on searching for the circulating antigens galactomannan and 1,3-β-D-glucan in the bronchoalveolar lavage fluid (bGM) or serum (sGM). In this study, to verify whether the COVID-19 period has stimulated clinicians to pay greater attention to IPA in patients with respiratory tract infections, we evaluated the number of requests for GM-Ag research and the number of positive tests found during the pre-COVID-19 and COVID-19 periods. Our data show a significant upward trend in GM-Ag requests and positivity from the pre-COVID to COVID period, which is attributable in particular to the increase in IPA risk factors as a complication of COVID-19. In the COVID period, parallel to the increase in requests, the number of positive tests for GM-Ag also increased, going from 2.5% in the first period of 2020 to 12.3% in the first period of 2021

2019-20 coronavirus outbreak · Aspergillosis · Aspergillus · Biology · Bronchoalveolar lavage · Bronchoscopy · Coronavirus disease 2019 (COVID-19 · Disease · Galactomannan · Infectious disease (medical specialty · Lung · Outbreak · Pathology · Pulmonary aspergillosis · Respiratory system · Respiratory tract · Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 · Antifungal resistance and susceptibility · Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Medicine · Nosocomial Infections in ICU · Immunology · Internal Medicine · Microbiology

Tools

Open DOIOpen Access